Header

UZH-Logo

Maintenance Infos

Publications for Schraml, P

Navigate back| Up a level
Export as
Group by:
Number of items: 64.

2018

Velagapudi, Srividya; Schraml, Peter; Yalcinkaya, Mustafa; Bolck, Hella Anna; Rohrer, Lucia; Moch, Holger; von Eckardstein, Arnold (2018). Scavenger receptor BI promotes cytoplasmic accumulation of lipoproteins in clear-cell renal cell carcinoma. Journal of Lipid Research, 59(11):2188-2201.

Posch, Florian; Silina, Karina; Leibl, Sebastian; Mündlein, Axel; Moch, Holger; Siebenhüner, Alexander; Samaras, Panagiotis; Riedl, Jakob; Stotz, Michael; Szkandera, Joanna; Stöger, Herbert; Pichler, Martin; Stupp, Roger; van den Broek, Maries; Schraml, Peter; Gerger, Armin; Petrausch, Ulf; Winder, Thomas (2018). Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. OncoImmunology, 7(2):e1378844.

2017

Janouskova, Hana; El Tekle, Geniver; Bellini, Elisa; Udeshi, Namrata D; Rinaldi, Anna; Ulbricht, Anna; Bernasocchi, Tiziano; Civenni, Gianluca; Losa, Marco; Svinkina, Tanya; Bielski, Craig M; Kryukov, Gregory V; Cascione, Luciano; Napoli, Sara; Enchev, Radoslav I; Mutch, David G; Carney, Michael E; Berchuck, Andrew; Winterhoff, Boris J N; Broaddus, Russell R; Schraml, Peter; Moch, Holger; Bertoni, Francesco; Catapano, Carlo V; Peter, Matthias; Carr, Steven A; Garraway, Levi A; Wild, Peter J; Theurillat, Jean-Philippe P (2017). Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nature Medicine, 23(9):1046-1054.

Razafinjatovo, Caroline Fanja; Stiehl, Daniel; Deininger, Eva; Rechsteiner, Markus; Moch, Holger; Schraml, Peter (2017). VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma. OncoTarget, 8(6):10199-10212.

Hofmann, Ariane L; Behr, Jonas; Singer, Jochen; Kuipers, Jack; Beisel, Christian; Schraml, Peter; Moch, Holger; Beerenwinkel, Niko (2017). Detailed simulation of cancer exome sequencing data reveals differences and common limitations of variant callers. BMC Bioinformatics, 18(1):8.

Varga, Zsuzsanna; Lebeau, Annette; Bu, Hong; Hartmann, Arndt; Penault-Llorca, Frederique; Guerini-Rocco, Elena; Schraml, Peter; Symmans, Fraser; Stoehr, Robert; Teng, Xiaodong; Turzynski, Andreas; von Wasielewski, Reinhard; Gürtler, Claudia; Laible, Mark; Schlombs, Kornelia; Joensuu, Heikki; Keller, Thomas; Sinn, Peter; Sahin, Ugur; Bartlett, John; Viale, Giuseppe (2017). An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®. Breast Cancer Research, 19:55.

Cors, Julien F; Kashyap, Aditya; Fomitcheva Khartchenko, Anna; Schraml, Peter; Kaigala, Govind V (2017). Tissue lithography: Microscale dewaxing to enable retrospective studies on formalin-fixed paraffin-embedded (FFPE) tissue sections. PLoS ONE, 12(5):1-14.

2016

Lukamowicz-Rajska, Magdalena; Mittmann, Christiane; Prummer, Michael; Zhong, Qing; Bedke, Jens; Hennenlotter, Jörg; Stenzl, Arnulf; Mischo, Axel; Bihr, Svenja; Schmidinger, Manuela; Vogl, Ursula; Blume, Iris; Karlo, Christoph; Schraml, Peter; Moch, Holger (2016). MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients. OncoTarget:15.

Ruf, Melanie; Moch, Holger; Schraml, Peter (2016). PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. International Journal of Cancer, 139(2):396-403.

Stracquadanio, Giovanni; Vrugt, Bart; Flury, Renata; Schraml, Peter; Würl, Peter; Müller, Thomas H; Knippschild, Uwe; Henne-Bruns, Doris; Breitenstein, Stefan; Clavien, Pierre-Alain; Graf, Rolf; Bond, Gareth L; Grochola, Lukasz F (2016). CD44 SNP rs187115: A novel biomarker signature that predicts survival in resectable pancreatic ductal adenocarcinoma. Clinical Cancer Research:31.

Nowicka, A M; Häuselmann, I; Borsig, L; Bolduan, S; Schindler, M; Schraml, P; Heikenwalder, M; Moch, H (2016). A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization. Oncogene, 35(24):3125-3138.

Razafinjatovo, Caroline; Bihr, Svenja; Mischo, Axel; Vogl, Ursula; Schmidinger, Manuela; Moch, Holger; Schraml, Peter (2016). Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. BMC Cancer, 16:638.

Beleut, Manfred; Soeldner, Robert; Egorov, Mark; Guenther, Rolf; Dehler, Silvia; Morys-Wortmann, Corinna; Moch, Holger; Henco, Karsten; Schraml, Peter (2016). Discretization of Gene Expression Data Unmasks Molecular Subgroups Recurring in Different Human Cancer Types. PLoS ONE, 11(8):e0161514.

2015

Ruf, Melanie; Moch, Holger; Schraml, Peter (2015). Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma. OncoImmunology, 4(12):e1049805.

Ruf, Melanie; Mittmann, Christiane; Nowicka, Anna M; Hartmann, Arndt; Hermanns, Thomas; Poyet, Cédric; van den Broek, Maries; Sulser, Tullio; Moch, Holger; Schraml, Peter (2015). pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma. Clinical Cancer Research, 21(4):889-98.

Pflueger, Dorothee; Mittmann, Christiane; Dehler, Silvia; Rubin, Mark A; Moch, Holger; Schraml, Peter (2015). Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer. BMC Genomics, 16(247):online.

Eppler, Elisabeth; Janas, Eva; Link, Karl; Weidmann, Lukas; Bischofberger, Helena; Wenger, Michael; Tinguely, Marianne; Schraml, Peter; Moch, Holger; Fellbaum, Christian (2015). Insulin-like growth factor I is expressed in classical and nodular lymphocyte-predominant Hodgkin's lymphoma tumour and microenvironmental cells. Cell and Tissue Research, 359(3):841-851.

Schraml, Peter; Beleut, Manfred (2015). Microarrays and Renal Cell Cancer Biomarkers. In: Preedy, Victor R; Patel, Vinood B. Biomarkers in Cancer. Dordrecht: Springer Science+Business Media, 273-301.

2014

Wyler, L; Napoli, C U; Ingold, B; Sulser, T; Heikenwälder, M; Schraml, P; Moch, H (2014). Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression. British Journal of Cancer, 110(3):686-694.

2013

Albers, Joachim; Rajski, Michal; Schönenberger, Désirée; Harlander, Sabine; Schraml, Peter; von Teichman, Adriana; Georgiev, Strahil; Wild, Peter J; Moch, Holger; Krek, Wilhelm; Frew, Ian J (2013). Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice. EMBO Molecular Medicine, 5(6):949-964.

Varga, Zsuzsanna; Sinn, Peter; Fritzsche, Florian; von Hochstetter, Arthur; Noske, Aurelia; Schraml, Peter; Tausch, Christoph; Trojan, Andreas; Moch, Holger (2013). Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer. PLoS ONE, 8(3):e58483.

Varga, Zsuzsanna; Sinn, Peter; Fritzsche, Florian; von Hochstetter, Arthur; Noske, Aurelia; Schraml, Peter; Tausch, Christoph; Trojan, Andreas; Moch, Holger (2013). Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer. PLoS ONE, 8(10):online.

Pflueger, Dorothee; Sboner, Andrea; Storz, Martina; Roth, Jasmine; Compérat, Eva; Bruder, Elisabeth; Rubin, Mark A; Schraml, Peter; Moch, Holger (2013). Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing. Neoplasia, 15(11):1231-1240.

Roth, P; Silginer, M; Goodman, S L; Hasenbach, K; Thies, S; Maurer, G; Schraml, P; Tabatabai, G; Moch, H; Tritschler, I; Weller, M (2013). Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain, 136(2):564-576.

Rechsteiner, Markus; von Teichman, Adriana; Rüschoff, Jan H; Fankhauser, Niklaus; Pestalozzi, Bernhard; Schraml, Peter; Weber, Achim; Wild, Peter; Zimmermann, Dieter; Moch, Holger (2013). KRAS, BRAF, and TP53 deep-sequencing for colorectal carcinoma patient diagnostics. Journal of Molecular Diagnostics, 15(3):299-311.

Pawłowski, Rafal; Mühl, Sarah M; Sulser, Tullio; Krek, Wilhelm; Moch, Holger; Schraml, Peter (2013). Loss of PBRM1 expression is associated with renal cell carcinoma progression. International Journal of Cancer, 132(2):E11-7.

Kaufmann, Muriel R; Schraml, Peter; Hermanns, Thomas; Wenger, Roland H; Camenisch, Gieri (2013). Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma. Experimental and Molecular Pathology, 94(3):453-457.

Dannenmann, Stefanie R; Hermanns, Thomas; Bransi, Ali; Matter, Claudia; von Boehmer, Lotta; Stevanovic, Stefan; Schraml, Peter; Moch, Holger; Knuth, Alexander; van den Broek, Maries (2013). Spontaneous peripheral T-cell responses toward the tumor-associated antigen cyclin D1 in patients with clear cell renal cell carcinoma. Cancer Immunology Research, 1(5):288-295.

Casagrande, Silvia; Ruf, Melanie; Rechsteiner, Markus; Morra, Laura; Brun-Schmid, Sonja; von Teichman, Adriana; Krek, Wilhelm; Schraml, Peter; Moch, Holger (2013). The Protein-Tyrosine Phosphatase Receptor Type J is regulated by the pVHL-HIF axis in Clear Cell Renal Cell Carcinoma. Journal of Pathology, 229(4):525-534.

Dannenmann, Stefanie Regine; Thielicke, Julia; Stöckli, Martina; Matter, Claudia; von Boehmer, Lotta; Cecconi, Virginia; Hermanns, Thomas; Hefermehl, Lukas; Schraml, Peter; Moch, Holger; Knuth, Alexander; van den Broek, Maries (2013). Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. OncoImmunology, 2(3):e23562.

Vogetseder, A; Thies, S; Ingold, B; Roth, P; Weller, M; Schraml, P; Goodman, S L; Moch, H (2013). αv-Integrin isoform expression in primary human tumors and brain metastases. International Journal of Cancer, 133(10):2362-2371.

2012

Boysen, Gunther; Bausch-Fluck, Damaris; Thoma, Claudio R; Nowicka, Anna M; Stiehl, Daniel P; Cima, Igor; Van-Duc, Luu; von Teichman, Adriana; Hermanns, Thomas; Sulser, Tullio; Ingold-Heppner, Barbara; Fankhauser, Niklaus; Wenger, Roland H; Krek, Wilhelm; Schraml, Peter; Wollscheid, Bernd; Moch, Holger (2012). Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma. Neoplasia, 14(6):535-546.

Morra, L; Rechsteiner, M; Casagrande, S; von Teichman, A; Schraml, P; Moch, H; Soltermann, A (2012). Characterization of periostin isoform pattern in non-small cell lung cancer. Lung Cancer, 76(2):183-190.

Denkert, C; Kronenwett, R; Schlake, W; Bohmann, K; Penzel, R; Weber, K E; Höfler, H; Lehmann, U; Schirmacher, P; Specht, K; Rudas, M; Kreipe, H H; Schraml, P; Schlake, G; Bago-Horvath, Z; Tiecke, F; Varga, Z; Moch, H; Schmidt, M; Prinzler, J; Kerjaschki, D; Sinn, B V; Müller, B M; Filipits, M; Petry, C; Dietel, M (2012). Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Archiv, 460(3):251-259.

Schoenewolf, Nicola L; Dummer, Reinhard; Mihic-Probst, Daniela; Moch, Holger; Simcock, Mathew; Ochsenbein, Adrian; Gillessen, Silke; Schraml, Peter; von Moos, Roger (2012). Detecting BRAF mutations in formalin-fixed melanoma: experiences with two state-of-the-art techniques. Case Reports in Oncology, 5(2):280-289.

Beleut, Manfred; Zimmermann, Philip; Baudis, Michael; Bruni, Nicole; Bühlmann, Peter; Laule, Oliver; Luu, Van-Duc; Gruissem, Wilhelm; Schraml, Peter; Moch, Holger (2012). Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome. BMC Cancer, 12:310.

Wiedl, T; Collaud, S; Hillinger, S; Arni, S; Burgess, C; Kroll, W; Schraml, P; Soltermann, A; Moch, H; Weder, W (2012). KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma. Cancer Genomics & Proteomics, 9(1):51-54.

Stiehl, D P; Bordoli, M R; Abreu-Rodríguez, I; Wollenick, K; Schraml, P; Gradin, K; Poellinger, L; Kristiansen, G; Wenger, R H (2012). Non-canonical HIF-2alpha function drives autonomous breast cancer cell growth via an AREG-EGFR/ErbB4 autocrine loop. Oncogene, 31(18):2283-2297.

Schraml, P; von Teichman, A; Mihic-Probst, D; Simcock, M; Ochsenbein, A; Dummer, R; Michieilin, O; Seifert, B; Schläppi, M; Moch, H; von Moos, R (2012). Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncology Reports, 28(2):654-658.

Gerstung, Moritz; Beisel, Christian; Rechsteiner, Markus; Wild, Peter; Schraml, Peter; Moch, Holger; Beerenwinkel, Niko (2012). Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nature Communications, 3:811.

Wollenick, K; Hu, J; Kristiansen, G; Schraml, P; Rehrauer, H; Berchner-Pfannschmidt, U; Fandrey, J; Wenger, R H; Stiehl, D P (2012). Synthetic transactivation screening reveals ETV4 as broad coactivator of hypoxia-inducible factor signaling. Nucleic Acids Research, 40(5):1928-1943.

Mihic-Probst, Daniela; Ikenberg, Kristian; Tinguely, Marianne; Schraml, Peter; Behnke, Silvia; Seifert, Burkhardt; Civenni, Gianluca; Sommer, Lukas; Moch, Holger; Dummer, Reinhard (2012). Tumor cell plasticity and angiogenesis in human melanomas. PLoS ONE, 7(3):e33571.

von Teichman, Adriana; Storz, Martina; Dettwiler, Susanne; Moch, Holger; Schraml, Peter (2012). Whole genome and transcriptome amplification: practicable tools for sustainable tissue biobanking? Virchows Archiv, 461(5):571-580.

2011

Suwaki, N; Vanhecke, E; Atkins, K M; Graf, M; Swabey, K; Huang, P; Schraml, P; Moch, H; Cassidy, A M; Brewer, D; Al-Lazikani, B; Workman, P; De-Bono, J; Kaye, S B; Larkin, J; Gore, M E; Sawyers, C L; Nelson, P; Beer, T M; Geng, H; Gao, L; Qian, D Z; Alumkal, J J; Thomas, G; Thomas, G V (2011). A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Science Translational Medicine, 3(85):85ra47.

Doberstein, K; Schramme, A; Lee, S B; Blaheta, R A; Wedel, S; Moch, H; Schraml, P; Pfeilschifter, J; Kristiansen, G; Gutwein, P (2011). L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. Carcinogenesis, 32(3):262-270.

Bordoli, M R; Stiehl, D P; Borsig, L; Kristiansen, G; Hausladen, S; Schraml, P; Wenger, R H; Camenisch, G (2011). Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis. Oncogene, 30(5):548-560.

Morra, L; Rechsteiner, M; Casagrande, S; Duc Luu, V; Santimaria, R; Diener, P A; Sulser, T; Kristiansen, G; Schraml, P; Moch, H; Soltermann, A (2011). Relevance of periostin splice variants in renal cell carcinoma. American Journal of Pathology, 179(3):1513-1521.

Rechsteiner, M P; von Teichman, A; Nowicka, A; Sulser, T; Schraml, P; Moch, H (2011). VHL gene mutations and their effects on hypoxia inducible factor HIF{alpha}: Identification of potential driver and passenger mutations. Cancer Research, 71(16):5500-5511.

Teichman, A V; Compérat, E; Behnke, S; Storz, M; Moch, H; Schraml, P (2011). VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma. Modern Pathology, 24(4):571-578.

2010

Probst-Hensch, N M; Steiner, J H B; Schraml, P; Varga, Z; Zürrer-Härdi, U; Storz, M; Korol, D; Fehr, M K; Fink, D; Pestalozzi, B C; Lütolf, U M; Theurillat, J P; Moch, H (2010). IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clinical Cancer Research, 16(3):1025-1032.

Dahinden, C; Ingold, B; Wild, P; Boysen, G; Luu, V D; Montani, M; Kristiansen, G; Sulser, T; Bühlmann, P; Moch, H; Schraml, P (2010). Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clinical Cancer Research, 16(1):88-98.

Tischler, V; Fritzsche, F R; Wild, P J; Stephan, C; Seifert, H H; Riener, M O; Hermanns, T; Mortezavi, A; Gerhardt, J; Schraml, P; Jung, K; Moch, H; Soltermann, A; Kristiansen, G (2010). Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer, 10:273.

2009

Balamurugan, K; Luu, V D; Kaufmann, M R; Hofmann, V S; Boysen, G; Barth, S; Bordoli, M R; Stiehl, D P; Moch, H; Schraml, P; Wenger, R H; Camenisch, G (2009). Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response. Oncogene:1-12.

Ingold, B; Schraml, P; Heppner, F L; Moch, H (2009). Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. PLoS ONE, 4(3):e4775.

Boysen, G; Wollscheid, B; Bausch-Fluck, D; Schraml, P; Moch, H (2009). Identifizierung VHL-assoziierter Veränderungen im klarzelligen Nierenzellkarzinom : Anwendung von kombinierten Genom- und Expressionsanalysen. Der Pathologe, Suppl 2:188-192.

Luu, V D; Boysen, G; Struckmann, K; Casagrande, S; von Teichman, A; Wild, P J; Sulser, T; Schraml, P; Moch, H (2009). Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clinical Cancer Research, 15(10):3297-3304.

Thoma, C R; Toso, A; Gutbrodt, K L; Reggi, S P; Frew, I J; Schraml, Peter; Hergovich, A; Moch, H; Meraldi, P; Krek, W (2009). VHL loss causes spindle misorientation and chromosome instability. Nature Cell Biology, 11(8):994-1001.

2008

Steu, S; Baucamp, M; von Dach, G; Bawohl, M; Dettwiler, S; Storz, M; Moch, H; Schraml, P (2008). A procedure for tissue freezing and processing applicable to both intra-operative frozen section diagnosis and tissue banking in surgical pathology. Virchows Archiv, 452(3):305-312.

Schraml, P; Frew, I J; Thoma, C R; Boysen, G; Struckmann, K; Krek, W; Moch, H (2008). Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. Modern Pathology, 22(1):31-36.

Luu, V D; Fischer, B; von Teichman, A; Boysen, G; Mertz, K; Zimmermann, P; Moch, H; Schraml, P (2008). Von-Hippel-Lindau-Gen-Mutationstypen: Assoziation mit Genexpressionssignaturen in klarzelligen Nierenzellkarzinomen. Der Pathologe, 29(Suppl.):303-307.

Struckmann, K; Mertz, K; Steu, S; Storz, M; Staller, P; Krek, W; Schraml, P; Moch, H (2008). pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. Journal of Pathology, 214(4):464-471.

2007

Mertz, Kirsten D; Demichelis, Francesca; Kim, Robert; Schraml, Peter; Storz, Martina; Diener, Pierre-André; Moch, Holger; Rubin, Mark A (2007). Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Human Pathology, 38(10):1454-1462.

Zhao, J; Yart, A; Frigerio, S; Perren, A; Schraml, P; Weisstanner, C; Stallmach, T; Krek, W; Moch, H (2007). Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene. Oncogene, 26(23):3440-3449.

Mihic-Probst, D; Kuster, A; Kilgus, S; Bode-Lesniewska, B; Ingold-Heppner, B; Leung, C; Storz, M; Seifert, Burkhardt; Marino, S; Schraml, P; Dummer, R; Moch, H (2007). Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. International Journal of Cancer, 121(8):1764-1770.

This list was generated on Sat Dec 15 19:34:49 2018 CET.